Caliway's CBL-514 Receives Early IND Clearance in China
Caliway Biopharmaceuticals' China clinical trial (CBL-0102) for the injectable drug candidate CBL-514 received early authorization to proceed from China's NMPA ahead of schedule, with subject enrollment expected to begin in December 2026 and clinical data anticipated in Q2 2027.
Why it matters. The early IND clearance accelerates Caliway's development timeline in China, the world's fastest-growing body contouring market projected to reach RMB 643 billion by 2040, and supports potential regulatory submissions across other Asian…